171 related articles for article (PubMed ID: 32859630)
1. Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells.
Jasek-Gajda E; Jurkowska H; JasiŃska M; Litwin JA; Lis GJ
Cancer Genomics Proteomics; 2020; 17(5):517-527. PubMed ID: 32859630
[TBL] [Abstract][Full Text] [Related]
2. Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.
Jasek-Gajda E; Jurkowska H; Jasińska M; Litwin JA; Lis GJ
Apoptosis; 2019 Dec; 24(11-12):849-861. PubMed ID: 31482470
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.
Wall NR; Mohammad RM; Al-Katib AM
Cell Growth Differ; 2001 Dec; 12(12):641-7. PubMed ID: 11751459
[TBL] [Abstract][Full Text] [Related]
4. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract][Full Text] [Related]
5. The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
Guo Y; Shan QQ; Gong PY; Wang SC
J Cancer Res Ther; 2018; 14(Supplement):S125-S131. PubMed ID: 29578162
[TBL] [Abstract][Full Text] [Related]
6. Quinalizarin Induces Apoptosis through Reactive Oxygen Species (ROS)-Mediated Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathways in Colorectal Cancer Cells.
Meng LQ; Wang Y; Luo YH; Piao XJ; Liu C; Wang Y; Zhang Y; Wang JR; Wang H; Xu WT; Liu Y; Wu YQ; Sun HN; Han YH; Jin MH; Shen GN; Fang NZ; Jin CH
Med Sci Monit; 2018 Jun; 24():3710-3719. PubMed ID: 29860266
[TBL] [Abstract][Full Text] [Related]
7. Glycitein induces reactive oxygen species-dependent apoptosis and G0/G1 cell cycle arrest through the MAPK/STAT3/NF-κB pathway in human gastric cancer cells.
Zang YQ; Feng YY; Luo YH; Zhai YQ; Ju XY; Feng YC; Wang JR; Yu CQ; Jin CH
Drug Dev Res; 2019 Aug; 80(5):573-584. PubMed ID: 30916421
[TBL] [Abstract][Full Text] [Related]
8. Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
Jin J; Guo Q; Xie J; Jin D; Zhu Y
Pathol Oncol Res; 2019 Apr; 25(2):769-775. PubMed ID: 30706361
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
[TBL] [Abstract][Full Text] [Related]
10. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
[TBL] [Abstract][Full Text] [Related]
11. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Kaneko N; Kita A; Yamanaka K; Mori M
Leuk Res; 2013 Sep; 37(9):1156-61. PubMed ID: 23746965
[TBL] [Abstract][Full Text] [Related]
12. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Dixon ZA; Nicholson L; Zeppetzauer M; Matheson E; Sinclair P; Harrison CJ; Irving JA
Haematologica; 2017 Apr; 102(4):736-745. PubMed ID: 27979926
[TBL] [Abstract][Full Text] [Related]
13. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3.
Yu ZY; Huang R; Xiao H; Sun WF; Shan YJ; Wang B; Zhao TT; Dong B; Zhao ZH; Liu XL; Wang SQ; Yang RF; Luo QL; Cong YW
Int J Cancer; 2010 Sep; 127(6):1259-70. PubMed ID: 20087863
[TBL] [Abstract][Full Text] [Related]
14. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
16. A new xanthatin analogue 1β-hydroxyl-5α-chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma.
Fang XY; Zhang H; Zhao L; Tan S; Ren QC; Wang L; Shen XF
Biochimie; 2018 Sep; 152():43-52. PubMed ID: 29960031
[TBL] [Abstract][Full Text] [Related]
17. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative potential of a novel parthenin analog P16 as evident by apoptosis accompanied by down-regulation of PI3K/AKT and ERK pathways in human acute lymphoblastic leukemia MOLT-4 cells.
Goswami A; Shah BA; Kumar A; Rizvi MA; Kumar S; Bhushan S; Malik FA; Batra N; Joshi A; Singh J
Chem Biol Interact; 2014 Oct; 222():60-7. PubMed ID: 25196075
[TBL] [Abstract][Full Text] [Related]
19. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
